PAR-22-085: Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 8, 2024.
From the official notice on Grants.gov, last changed November 8, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNCI, NIDCR
- Median yearly award$508,693
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under PAR-22-085 were run by National Cancer Institute (NCI, 12 projects) and National Institute of Dental and Craniofacial Research (NIDCR, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-085 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-107 | November 21, 2024 | Closed May 7, 2025 | Closed |
Key dates
| Posted | February 18, 2022 |
|---|---|
| Deadline | November 8, 2024 |
| Archived by Grants.gov | December 8, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 3 programs behind this notice (64% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy. (link to OCCAM)
Funded under PAR-22-085 so far
NIH funded 13 projects under PAR-22-085 in fiscal 2023 to 2026, at 10 institutions. The median yearly award was $508,693.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Reversing cancer immunosuppression using attenuated Listeria monocytogenes | University of California Berkeley | 2026 | $473,641 |
| Exploiting immunostimulatory microbial pattern recognition to improve head and neck cancer therapy | Virginia Commonwealth University | 2026 | $427,208 |
| Metabolism of cancer chemotherapeutics by the human gut microbiome | University of California, San Francisco | 2026 | $132,337 |
| Hypoxia-activated probiotic agents for breast cancer | University of Illinois at Chicago | 2026 | $364,569 |
| Targeting a human gut bacterial genotoxin via engineered commensal bacteria | University of Michigan at Ann Arbor | 2026 | $590,814 |
| Role of bacterial-derived small molecules in immunotherapy | University of Florida | 2026 | $540,288 |
| Employing Humanized Microbiome Mice to Understand Immune Activation and Translational Therapeutic Potential in Glioblastoma | University of Alabama at Birmingham | 2026 | $329,317 |
| The role of the mycobiome in cancer | Weill Medical Coll of Cornell Univ | 2026 | $508,693 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Oral Diseases and Disorders Research grants before
From fiscal 2021 to 2025, Oral Diseases and Disorders Research (93.121) awarded $1.9 billion across 2,263 grant awards, an average of $818,037 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 76 | $89.2 million |
| The Regents of the University of California, San Francisco | California | 84 | $80.5 million |
| University of Southern California | California | 41 | $78.6 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 58 | $55.9 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 66 | $51.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-085 still open?
No. It closed on November 8, 2024.
Who can apply for Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)?
Closed November 8, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-085?
NIH RePORTER lists 13 projects funded under PAR-22-085 in fiscal 2023 to 2026, at 10 institutions. The most were at University of Michigan at Ann Arbor, Weill Medical Coll of Cornell Univ, University of TX MD Anderson Can Ctr.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)